Evidence map›Paper›PMID 35093024›Full record

ArticleMolecular medicine (Cambridge, Mass.)2022

Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation.

Lin Li, Wen-Jun Li, Xiang-Ru Zheng, Qing-Long Liu, Qian Du, Yu-Jie Lai, Song-Qing Liu

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 149 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Non-canonical cell death in neurodegeneration: emerging mechanisms and therapeutic Frontiers.Apoptosis : an international journal on programmed cell death · 2026
    Review
  10. Alzheimer's disease prevention by flavonols and their analogs.The journal of prevention of Alzheimer's disease · 2026
    Review
  11. Vitamin DFrontiers in immunology · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lin Li *Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Shuanghu Road, Yubei District, Chongqing, 401120, People's Republic of China.
Wen-Jun Li *Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Shuanghu Road, Yubei District, Chongqing, 401120, People's Republic of China.
Xiang-Ru ZhengDepartment of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China.
Qing-Long LiuDepartment of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Shuanghu Road, Yubei District, Chongqing, 401120, People's Republic of China.
Qian DuDepartment of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Shuanghu Road, Yubei District, Chongqing, 401120, People's Republic of China.
Yu-Jie LaiDepartment of Neurology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China. laiyujie0206@163.com.
Song-Qing LiuDepartment of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Shuanghu Road, Yubei District, Chongqing, 401120, People's Republic of China. liusq@hospital.cqmu.edu.cn.ORCID 0000-0002-9269-3961
Chongqing Medical University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNThird People 's Hospital of Chongqing · CN

Funding

Application and Development Project from Chongqing Science and Technology Commission cstc2020jscx-msxmX0123Chongqing Basic Research and Frontier Exploration Project cstc2018jcyjAX0170National Natural Science Foundation of China 81801071
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is the most common type of neurodegenerative disease in the contemporary era, and it is still clinically incurable. Eriodictyol, a natural flavonoid compound that is mainly present in citrus fruits and some Chinese herbal medicines, has been reported to exert anti-inflammatory, antioxidant, anticancer and neuroprotective effects. However, few studies have examined the anti-AD effect and molecular mechanism of eriodictyol.

methodsAPP/PS1 mice were treated with eriodictyol and the cognitive function of mice was assessed using behavioral tests. The level of amyloid-β (Aβ) aggregation and hyperphosphorylation of Tau in the mouse brain were detected by preforming a histological analysis and Western blotting. HT-22 cells induced by amyloid-β peptide (1-42) (Aβ

resultsEriodictyol obviously ameliorated cognitive deficits in APP/PS1 mice, and suppressed Aβ aggregation and Tau phosphorylation in the brains of APP/PS1 mice. Moreover, eriodictyol inhibited Tau hyperphosphorylation and neurotoxicity in HT-22 cells induced by Aβ

conclusionsEriodictyol alleviated memory impairment and AD-like pathological changes by activating the Nrf2/HO-1 signaling pathway through a mechanism mediated by VDR, which provides a new possibility for the treatment of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBiomarkersCognitionDisease Models, AnimalDisease SusceptibilityFemaleFerroptosisFlavanonesImmunohistochemistryMiceMice, TransgenicNF-E2-Related Factor 2PhosphorylationAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, mouseBiomarkerseriodictyolFlavanonesNF-E2-Related Factor 2Reactive Oxygen SpeciesReceptors, Calcitrioltau ProteinsAlzheimer’s diseaseEriodictyolFerroptosisNrf2VDR

Identifiers

PMID35093024
PMCPMC8800262
OpenAlexW4210538269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.